Total labs
30
Total footprint
30,000 sq ft
Set to open in 2026, OMX will offer the much-needed lab space needed to scale growing Deep Tech companies — and it will do so within the supportive, well-connected ecosystem built by Science Creates.
Join our community of scientific entrepreneurs developing technologies that include groundbreaking cancer treatments, enhanced battery technologies and seaweed-based biomaterials.
Located in the heart of Bristol and connected to our Old Market incubator, OMX is designed with the specialised services and features that Deep Tech R&D demands, plus the flexibility that growing ventures need.
With 30,000 sq ft of lab, office and meeting space, OMX offers a range of options depending on the size of your company — from lab-only options to full suites including two labs and a private office.
Membership includes access to our platform of support, providing opportunities to attend workshops and events, connect with other founders, and find a mentor.





Express your interest to secure a space at our newest Bristol incubator.



Travel between locations is measured in walking distance
St Philips Rd & Midland Rd
0.5 miles / 11 min
0.7 miles / 15 min

Lifecare is committed to improving the lives of people and pets with diabetes. It is developing the next-generation of miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers to the market. The company’s spin-off entity Lifecare Chemistry Ltd was founded to enhance research collaboration and secure ownership of its improved analyte-specific chemical receptor developments.

neo-fossil is developing new technology using cell engineering to help reverse the threat of climate change. By optimising biology, it is creating new fossils that harvest atmospheric carbon dioxide, storing it for centuries.

Zentraxa is precision engineering biomaterials, pushing the boundaries of biopolymer synthesis to develop sustainable, performance-enhancing ingredients for everyday products. Its proprietary technological platform (Zentide) overcomes the biodesign limits of existing, conventional peptide synthesis by designing, producing and testing complex, novel peptides with one universal process. Zentraxa creates bespoke solutions for a range of industries by combining key features from different naturally-occurring proteins, such as stiffness, adhesion or thermal stability.




Fine Agrochemicals is enhancing crop quality for fruit and flower growers in agricultural, ornamental and landscape markets using its plant growth regulator (PGR) technology. Its PGR products, made using naturally occurring molecules through fermentation and combined with chemically synthesised compounds, help stimulate plant cells to enhance nutrient levels and targeted growth for improved crop outputs.

EnsiliTech is improving the shelf-life and global accessibility of vaccines and other biological therapeutics by combatting cold chain transport and storage issues. Its novel ensilication technology, designed for both existing and new biopharmaceutical formulations, encases thermally unstable biomolecules within silica nanoshells to prevent environmental degradation. This eliminates the need for cold chain requirements that are expensive, prone to failure and generate significant carbon dioxide emissions.

NuNano is advancing the field of atomic force microscopy with high-precision probes for nanometer-scale imaging. Its proprietary microfabrication processes produce reliable, high-quality probes with market-leading dimensional tolerances. It also provides dedicated support to its customers, from probe selection to storage, for a seamless user experience.




Transdermal Diagnostics is pioneering the development of bio-wearables that enhance the prevention, diagnosis and management of chronic conditions like diabetes. Its unique sensing technology aims to create the world’s first needle-free continuous monitor for glucose and other health biomarkers. By analysing hair follicles, the adhesive skin patch and transmitter wirelessly communicate information straight to a smartphone app, facilitating a transformative shift in patient care and quality of life for those with diabetes.

Hone Bio is revolutionising drug delivery using lipid nanoparticles (LNPs) and exploring their potential across multiple therapeutics, including cell and gene therapies, vaccines and autoimmune diseases. Its NanoPilot platform technology engineers LNPs to target specific cell types with extreme precision to optimise drug effectiveness by minimising off-target effects that tend to accumulate in the liver. This unlocks new possibilities for using LNPs to safely treat diseases in other parts of the body that require maximum target specificity in their drug delivery.

neo-fossil is developing new technology using cell engineering to help reverse the threat of climate change. By optimising biology, it is creating new fossils that harvest atmospheric carbon dioxide, storing it for centuries.


